[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
Mazeron
J-J
JJ
Service d'oncologie radiothérapique, groupe hospitalier Pitié-Salpêtrière, AP-HP, 47-83, boulevard de l'hôpital, 75651 Paris cedex 13, France. jean-jacques.mazeron@psl.ap-hop-paris.fr
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004999:Amifostine / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D005500:Follow-Up Studies; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008408:Mastectomy; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000097:blood / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D011837:Radiation-Protective Agents; D017430:Prostate-Specific Antigen; D004999:Amifostine; D002945:Cisplatin; D005472:Fluorouracil; D008727:Methotrexate